29 November 2017

Brexit and Life Sciences - the perfect storm

While it has been business as usual for the life sciences sector after the service of the Article 50 notice by the UK, come 29 March 2019, it is likely that this sector will be one of those most affected by Brexit; particularly in the UK, which has a strong track record in the life sciences. Pharmaceutical companies and, to a lesser extent medical device companies, need to anticipate regulatory steps that will be carried out as a consequence of Brexit so that they can continue to operate and supply the UK and EEA markets smoothly.

Document ID: 2017-6013